ViiV presents positive long-term data for combined HIV treatment
pharmafile | March 8, 2021 | News story | Sales and Marketing | HIV, ViiV Healthcare
ViiV Healthcare has presented positive long-term data from its global Phase IIIb ATLAS-2M study of the first complete, long-acting regimen of cabotegravir and rilpivirine for the treatment of HIV.
Findings at week 96 reinforce the primary and secondary endpoints initially assessed at week 48, and now show efficacy of both monthly dosing and every-two-month dosing over the long-term in virologically suppressed adults with HIV-1.
ATLAS-2M met its primary endpoint at week 48, demonstrating that the efficacy of long-acting cabotegravir and rilpivirine dosed every two months was non-inferior to monthly. Week 96 findings reinforced the primary endpoint, confirming that every-two-month and monthly doses of the drug combination are similarly effective.
The 96-week ATLAS-2M study showed that rates of virologic suppression were similar between the two arms, with 91% of participants in the every-two-month dosing arm and 90.2% in the monthly dosing arm achieving an HIV-1 viral load of 50 c/mL or less.
ViiV Healthcare’s cabotegravir in combination with Janssen’s rilpivirine was co-developed as part of a collaboration with Janssen.
Dr Hans Jäeger, former Medical Director of MVZ Karlsplatz, HIV Research and Clinical Care Centre, Munich, and investigator for the ATLAS-2M study, said: “The ATLAS-2M 96-week data reinforces the therapeutic potential of this long-acting regimen for the treatment of HIV. It provides an option that could change the treatment experience for some people living with HIV by removing the need for daily pills for the treatment of HIV.
“Taking a pill every day can come as an unwelcome daily reminder of their HIV status or it may add to their fears that their HIV status might be disclosed by someone seeing their HIV medication. This regimen can enable people living with HIV to reduce the days they receive treatment from 365 to 12 or six per year, representing a paradigm shift in their experience of HIV treatment.”
Dr Kimberly Smith, Head of Research & Development at ViiV Healthcare, also commented: “At ViiV Healthcare, our research and development is underpinned by a commitment to innovation and a desire to make a difference to the lives of people living with HIV.
“Long-acting cabotegravir and rilpivirine is a first-of-its-kind regimen that removes the need for daily therapies after the initiation phase. These long-term data confirm that every-two-month dosing is non-inferior to monthly dosing, which means people living with HIV who are virologically suppressed can reduce the number of days they take treatment to six times per year, allowing more time between doses with this regimen.”
Darcy Jimenez
Related Content
Gilead and Merck share data from phase 2 trial of HIV treatment
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, …
China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved …
